Trial
NCT03269552
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
Condition
Marginal Zone Lymphoma
Intervention
Carfilzomib
Why stopped
Terminated due to low accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-18